The role of interleukin‑6‑STAT3 signalling in glioblastoma (Review)
- Authors:
- Alice J. West
- Vanessa Tsui
- Stanley S. Stylli
- Hong P.T. Nguyen
- Andrew P. Morokoff
- Andrew H. Kaye
- Rodney B. Luwor
-
Affiliations: Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC 3050, Australia - Published online on: July 27, 2018 https://doi.org/10.3892/ol.2018.9227
- Pages: 4095-4104
-
Copyright: © West et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Aldape K, Zadeh G, Mansouri S, Reifenberger G and von Deimling A: Glioblastoma: Pathology, molecular mechanisms and markers. Acta Neuropathol. 129:829–848. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Agnihotri S, Burrell KE, Wolf A, Jalali S, Hawkins C, Rutka JT and Zadeh G: Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch Immunol Ther Exp (Warsz). 61:25–41. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Tully PA, Gogos AJ, Love C, Liew D, Drummond KJ and Morokoff AP: Reoperation for recurrent glioblastoma and its association with survival benefit. Neurosurgery. 79:678–689. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Desbaillets I, Diserens AC, Tribolet N, Hamou MF and Van Meir EG: Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J Exp Med. 186:1201–1212. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Shan Y, He X, Song W, Han D, Niu J and Wang J: Role of IL-6 in the invasiveness and prognosis of glioma. Int J Clin Exp Med. 8:9114–9120. 2015.PubMed/NCBI | |
|
Jarnicki A, Putoczki T and Ernst M: Stat3: Linking inflammation to epithelial cancer-more than a ‘gut’ feeling? Cell Div. 5:142010. View Article : Google Scholar : PubMed/NCBI | |
|
Kumari N, Dwarakanath BS, Das A and Bhatt AN: Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 37:11553–11572. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Iliopoulos D, Hirsch HA and Struhl K: An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 139:693–706. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Akira S and Kishimoto T: IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol Rev. 127:25–50. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Wu CT, Chen MF, Chen WC and Hsieh CC: The role of IL-6 in the radiation response of prostate cancer. Radiat Oncol. 8:1592013. View Article : Google Scholar : PubMed/NCBI | |
|
Yang R, Lin Q, Gao HB and Zhang P: Stress-related hormone norepinephrine induces interleukin-6 expression in GES-1 cells. Braz J Med Biol Res. 47:101–109. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Scheller J, Chalaris A, Schmidt-Arras D and Rose-John S: The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 1813:878–888. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Gruys E, Toussaint MJ, Niewold TA and Koopmans SJ: Acute phase reaction and acute phase proteins. J Zhejiang Univ Sci B. 6:1045–1056. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Tilg H, Trehu E, Atkins MB, Dinarello CA and Mier JW: Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 83:113–118. 1994.PubMed/NCBI | |
|
Aderka D, Le JM and Vilcek J: IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol. 143:3517–3523. 1989.PubMed/NCBI | |
|
Jones SA, Scheller J and Rose-John S: Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 121:3375–3383. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Mihara M, Hashizume M, Yoshida H, Suzuki M and Shiina M: IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 122:143–159. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Goswami S, Gupta A and Sharma SK: Interleukin-6-mediated autocrine growth promotion in human glioblastoma multiforme cell line U87MG. J Neurochem. 71:1837–1845. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Taga T and Kishimoto T: Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol. 15:797–819. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Chalaris A, Garbers C, Rabe B, Rose-John S and Scheller J: The soluble interleukin 6 receptor: Generation and role in inflammation and cancer. Eur J Cell Biol. 90:484–494. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Jones SA, Horiuchi S, Topley N, Yamamoto N and Fuller GM: The soluble interleukin 6 receptor: Mechanisms of production and implications in disease. FASEB J. 15:43–58. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshida K, Taga T, Saito M, Suematsu S, Kumanogoh A, Tanaka T, Fujiwara H, Hirata M, Yamagami T, Nakahata T, et al: Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci USA. 93:pp. 407–411. 1996; View Article : Google Scholar : PubMed/NCBI | |
|
Yeung YT, McDonald KL, Grewal T and Munoz L: Interleukins in glioblastoma pathophysiology: Implications for therapy. Br J Pharmacol. 168:591–606. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Rolhion C, Penault-Llorca F, Kémény JL, Lemaire JJ, Jullien C, Labit-Bouvier C, Finat-Duclos F and Verrelle P: Interleukin-6 overexpression as a marker of malignancy in human gliomas. J Neurosurg. 94:97–101. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Tchirkov A, Khalil T, Chautard E, Mokhtari K, Véronèse L, Irthum B, Vago P, Kémény JL and Verrelle P: Interleukin-6 gene amplification and shortened survival in glioblastoma patients. Br J Cancer. 96:474–476. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kudo M, Jono H, Shinriki S, Yano S, Nakamura H, Makino K, Hide T, Muta D, Ueda M, Ota K, et al: Antitumor effect of humanized anti-interleukin-6 receptor antibody (tocilizumab) on glioma cell proliferation. Laboratory investigation. J Neurosurg. 111:219–225. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Van Meir E, Sawamura Y, Diserens AC, Hamou MF and de Tribolet N: Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res. 50:6683–6688. 1990.PubMed/NCBI | |
|
Ashizawa T, Miyata H, Iizuka A, Komiyama M, Oshita C, Kume A, Nogami M, Yagoto M, Ito I, Oishi T, et al: Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma. Int J Oncol. 43:219–227. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhong Z, Wen Z and Darnell JE Jr: Stat3 and Stat4: Members of the family of signal transducers and activators of transcription. Proc Natl Acad Sci USA. 91:pp. 4806–4810. 1994; View Article : Google Scholar : PubMed/NCBI | |
|
Bromberg JF, Horvath CM, Besser D, Lathem WW and Darnell JE Jr: Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol. 18:2553–2558. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Ouédraogo ZG, Biau J, Kemeny JL, Morel L, Verrelle P and Chautard E: Role of STAT3 in genesis and progression of human malignant gliomas. Mol Neurobiol. 54:5780–5797. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Smilowitz HM, Weissenberger J, Weis J, Brown JD, O'Neill RJ and Laissue JA: Orthotopic transplantation of v-src-expressing glioma cell lines into immunocompetent mice: Establishment of a new transplantable in vivo model for malignant glioma. J Neurosurg. 106:652–659. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Dechow TN, Pedranzini L, Leitch A, Leslie K, Gerald WL, Linkov I and Bromberg JF: Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA. 101:pp. 10602–10607. 2004; View Article : Google Scholar : PubMed/NCBI | |
|
Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP and Jove R: Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol. 18:2545–2552. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernández-Luna JL, Nuñez G, et al: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 10:105–115. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS and Tweardy DJ: Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth in vitro. J Clin Invest. 102:1385–1392. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA and Haque SJ: Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene. 21:8404–8413. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Sherry MM, Reeves A, Wu JK and Cochran BH: STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells. 27:2383–2392. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kohsaka S, Wang L, Yachi K, Mahabir R, Narita T, Itoh T, Tanino M, Kimura T, Nishihara H and Tanaka S: STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Mol Cancer Ther. 11:1289–1299. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Heimberger AB: The therapeutic potential of inhibitors of the signal transducer and activator of transcription 3 for central nervous system malignancies. Surg Neurol Int. 2:1632011. View Article : Google Scholar : PubMed/NCBI | |
|
Waldner MJ, Foersch S and Neurath MF: Interleukin-6-a key regulator of colorectal cancer development. Int J Biol Sci. 8:1248–1253. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Culig Z and Puhr M: Interleukin-6: A multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol. 360:52–58. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Dethlefsen C, Højfeldt G and Hojman P: The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat. 138:657–664. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Macciò A and Madeddu C: The role of interleukin-6 in the evolution of ovarian cancer: Clinical and prognostic implications-a review. J Mol Med (Berl). 91:1355–1368. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Miura T, Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Takahashi H, Furuse J, Inagaki M, Higashi S, Kato H, et al: Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels. Pancreas. 44:756–763. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chang CH, Hsiao CF, Yeh YM, Chang GC, Tsai YH, Chen YM, Huang MS, Chen HL, Li YJ, Yang PC, et al: Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int J Cancer. 132:1977–1985. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN and Hsieh CY: Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene. 22:1517–1527. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Weissenberger J, Loeffler S, Kappeler A, Kopf M, Lukes A, Afanasieva TA, Aguzzi A and Weis J: IL-6 is required for glioma development in a mouse model. Oncogene. 23:3308–3316. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Q, Li G, Li R, Shen J, He Q, Deng L, Zhang C and Zhang J: IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J Neurooncol. 100:165–176. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Li R, Li G, Deng L, Liu Q, Dai J, Shen J and Zhang J: IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1. Oncol Rep. 23:1553–1559. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Anton K, Banerjee D and Glod J: Macrophage-associated mesenchymal stem cells assume an activated, migratory, pro-inflammatory phenotype with increased IL-6 and CXCL10 secretion. PLoS One. 7:e350362012. View Article : Google Scholar : PubMed/NCBI | |
|
Carmeliet P: Angiogenesis in life, disease and medicine. Nature. 438:932–936. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Garonna E, Botham KM, Birdsey GM, Randi AM, Gonzalez-Perez RR and Wheeler-Jones CP: Vascular endothelial growth factor receptor-2 couples cyclo-oxygenase-2 with pro-angiogenic actions of leptin on human endothelial cells. PLoS One. 6:e188232011. View Article : Google Scholar : PubMed/NCBI | |
|
Shibuya M: Vascular endothelial growth factor and its receptor system: Physiological functions in angiogenesis and pathological roles in various diseases. J Biochem. 153:13–19. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Labussière M, Cheneau C, Prahst C, Gállego Pérez-Larraya J, Farina P, Lombardi G, Mokhtari K, Rahimian A, Delattre JY, Eichmann A and Sanson M: Angiopoietin-2 may be involved in the resistance to bevacizumab in recurrent glioblastoma. Cancer Invest. 34:39–44. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou YH, Tan F, Hess KR and Yung WK: The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res. 9:3369–3375. 2003.PubMed/NCBI | |
|
Bergers G and Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 8:592–603. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Takano S: Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation. Brain Tumor Pathol. 29:73–86. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H, Bridges E, Shi W, Snell C, Bowden ET, et al: DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res. 71:6073–6083. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Peterson TE, Kirkpatrick ND, Huang Y, Farrar CT, Marijt KA, Kloepper J, Datta M, Amoozgar Z, Seano G, Jung K, et al: Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci USA. 113:pp. 4470–4475. 2016; View Article : Google Scholar : PubMed/NCBI | |
|
Tabouret E, Denicolai E, Delfino C, Graillon T, Boucard C, Nanni I, Padovani L, Figarella-Branger D and Chinot O: Changes in PlGF and MET-HGF expressions in paired initial and recurrent glioblastoma. J Neurooncol. 130:431–437. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Piao Y, Liang J, Holmes L, Henry V, Sulman E and de Groot JF: Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res. 19:4392–4403. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wesche J, Haglund K and Haugsten EM: Fibroblast growth factors and their receptors in cancer. Biochem J. 437:199–213. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Fu Z, Chen X, Guan S, Yan Y, Lin H and Hua ZC: Curcumin inhibits angiogenesis and improves defective hematopoiesis induced by tumor-derived VEGF in tumor model through modulating VEGF-VEGFR2 signaling pathway. Oncotarget. 6:19469–19482. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wu XY, Xu H, Wu ZF, Chen C, Liu JY, Wu GN, Yao XQ, Liu FK, Li G and Shen L: Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models. Oncotarget. 6:44563–44578. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Waxman AB and Kolliputi N: IL-6 protects against hyperoxia-induced mitochondrial damage via Bcl-2-induced Bak interactions with mitofusins. Am J Respir Cell Mol Biol. 41:385–396. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hirano T, Ishihara K and Hibi M: Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 19:2548–2556. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, et al: Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res. 12:11–19. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Clarke MF and Fuller M: Stem cells and cancer: Two faces of eve. Cell. 124:1111–1115. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA and Dick JE: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 367:645–648. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Magee JA, Piskounova E and Morrison SJ: Cancer stem cells: Impact, heterogeneity, and uncertainty. Cancer Cell. 21:283–296. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Willyard C: Stem cells: Bad seeds. Nature. 498:S12–S13. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F and Vescovi A: Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64:7011–7021. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J and Dirks PB: Identification of a cancer stem cell in human brain tumors. Cancer Res. 63:5821–5828. 2003.PubMed/NCBI | |
|
Hossain A, Gumin J, Gao F, Figueroa J, Shinojima N, Takezaki T, Priebe W, Villarreal D, Kang SG, Joyce C, et al: Mesenchymal stem cells isolated from human gliomas increase proliferation and maintain stemness of glioma stem cells through the IL-6/gp130/STAT3 pathway. Stem Cells. 33:2400–2415. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Jafri NF, Clarke JL, Weinberg V, Barani IJ and Cha S: Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. Neuro Oncol. 15:91–96. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Young GS, Macklin EA, Setayesh K, Lawson JD, Wen PY, Norden AD, Drappatz J and Kesari S: Longitudinal MRI evidence for decreased survival among periventricular glioblastoma. J Neurooncol. 104:261–269. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kroon P, Berry PA, Stower MJ, Rodrigues G, Mann VM, Simms M, Bhasin D, Chettiar S, Li C, Li PK, et al: JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. Cancer Res. 73:5288–5298. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, et al: The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24stem cell-like breast cancer cells in human tumors. J Clin Invest. 121:2723–2735. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Schroeder A, Herrmann A, Cherryholmes G, Kowolik C, Buettner R, Pal S, Yu H, Müller-Newen G and Jove R: Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. Cancer Res. 74:1227–1237. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou B, Damrauer JS, Bailey ST, Hadzic T, Jeong Y, Clark K, Fan C, Murphy L, Lee CY, Troester MA, et al: Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. J Clin Invest. 124:553–563. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Guo X, Qiu J, Tu T, Yang X, Deng L, Anders RA, Zhou L and Fu YX: Induction of innate lymphoid cell-derived interleukin-22 by the transcription factor STAT3 mediates protection against intestinal infection. Immunity. 40:25–39. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM, Eyler CE, Elderbroom J, Gallagher J, Schuschu J, et al: Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells. 27:2393–2404. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Giladi ND, Ziv-Av A, Lee HK, Finniss S, Cazacu S, Xiang C, Waldman Ben-Asher H, deCarvalho A, Mikkelsen T, Poisson L and Brodie C: RTVP-1 promotes mesenchymal transformation of glioma via a STAT-3/IL-6-dependent positive feedback loop. Oncotarget. 6:22680–22697. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Li GH, Wei H, Lv SQ, Ji H and Wang DL: Knockdown of STAT3 expression by RNAi suppresses growth and induces apoptosis and differentiation in glioblastoma stem cells. Int J Oncol. 37:103–110. 2010.PubMed/NCBI | |
|
Yu H, Lee H, Herrmann A, Buettner R and Jove R: Revisiting STAT3 signalling in cancer: New and unexpected biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Jackson C, Ruzevick J, Amin AG and Lim M: Potential role for STAT3 inhibitors in glioblastoma. Neurosurg Clin N Am. 23:379–389. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L, Wels J, Theilen T, Granitto S, Zhang X, et al: The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia. 15:848–862. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Liang Q, Ma C, Zhao Y, Gao G and Ma J: Inhibition of STAT3 reduces astrocytoma cell invasion and constitutive activation of STAT3 predicts poor prognosis in human astrocytoma. PLoS One. 8:e847232013. View Article : Google Scholar : PubMed/NCBI | |
|
Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, Irby R, Yeatman T, Courtneidge SA and Jove R: Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA. 98:pp. 7319–7324. 2001; View Article : Google Scholar : PubMed/NCBI | |
|
Hodge DR, Hurt EM and Farrar WL: The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 41:2502–2512. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kortylewski M and Yu H: Stat3 as a potential target for cancer immunotherapy. J Immunother. 30:131–139. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J and Jove R: Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science. 269:81–83. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Zhong Z, Wen Z and Darnell JE Jr: Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 264:95–98. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Elliott LH, Brooks WH and Roszman TL: Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors. J Clin Invest. 86:80–86. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Fletcher S, Drewry JA, Shahani VM, Page BD and Gunning PT: Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochem Cell Biol. 87:825–833. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Jing N and Tweardy DJ: Targeting Stat3 in cancer therapy. Anticancer Drugs. 16:601–607. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Leeman RJ, Lui VW and Grandis JR: STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther. 6:231–241. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Heinrich PC, Behrmann I, Müller-Newen G, Schaper F and Graeve L: Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 334:297–314. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SR, Bae MK, Kim JY, Wee HJ, Yoo MA and Bae SK: Aspirin induces apoptosis through the blockade of IL-6-STAT3 signaling pathway in human glioblastoma A172 cells. Biochem Biophys Res Commun. 387:342–347. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Shao H, Cheng HY, Cook RG and Tweardy DJ: Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res. 63:3923–3930. 2003.PubMed/NCBI | |
|
Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong LY, Fuller GN, Hiraoka N, Priebe W, Sawaya R and Heimberger AB: The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res. 14:8228–8235. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Tu Y, Zhong Y, Fu J, Cao Y, Fu G, Tian X and Wang B: Activation of JAK/STAT signal pathway predicts poor prognosis of patients with gliomas. Med Oncol. 28:15–23. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Minniti G, Muni R, Lanzetta G, Marchetti P and Enrici RM: Chemotherapy for glioblastoma: Current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res. 29:5171–5184. 2009.PubMed/NCBI | |
|
Baer JC, Freeman AA, Newlands ES, Watson AJ, Rafferty JA and Margison GP: Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer. 67:1299–1302. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Wang G, Weiss C, Sheng P and Bresnick E: Retrovirus-mediated transfer of the human O6-methylguanine-DNA methyltransferase gene into a murine hematopoietic stem cell line and resistance to the toxic effects of certain alkylating agents. Biochem Pharmacol. 51:1221–1218. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Piperi C, Themistocleous MS, Papavassiliou GA, Farmaki E, Levidou G, Korkolopoulou P, Adamopoulos C and Papavassiliou AG: High incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: Association with histopathological characteristics, inflammatory mediators and clinical outcome. Mol Med. 16:1–9. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Giometto B, Bozza F, Faresin F, Alessio L, Mingrino S and Tavolato B: Immune infiltrates and cytokines in gliomas. Acta Neurochir (Wien). 138:50–56. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Chang CY, Li MC, Liao SL, Huang YL, Shen CC and Pan HC: Prognostic and clinical implication of IL-6 expression in glioblastoma multiforme. J Clin Neurosci. 12:930–933. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Sasaki A, Ishiuchi S, Kanda T, Hasegawa M and Nakazato Y: Analysis of interleukin-6 gene expression in primary human gliomas, glioblastoma xenografts, and glioblastoma cell lines. Brain Tumor Pathol. 18:13–21. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, Priebe W and Heimberger AB: A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res. 67:9630–9636. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, et al: A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene. 26:2435–2444. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Stechishin OD, Luchman HA, Ruan Y, Blough MD, Nguyen SA, Kelly JJ, Cairncross JG and Weiss S: On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells. Neuro Oncol. 15:198–207. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
McFarland BC, Ma JY, Langford CP, Gillespie GY, Yu H, Zheng Y, Nozell SE, Huszar D and Benveniste EN: Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther. 10:2384–2393. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
He K, Qi Q, Chan CB, Xiao G, Liu X, Tucker-Burden C, Wang L, Mao H, Lu X, McDonald FE, et al: Blockade of glioma proliferation through allosteric inhibition of JAK2. Sci Signal. 6:ra552013. View Article : Google Scholar : PubMed/NCBI | |
|
Senft C, Priester M, Polacin M, Schröder K, Seifert V, Kögel D and Weissenberger J: Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells. J Neurooncol. 101:393–403. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lo HW, Cao X, Zhu H and Ali-Osman F: Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res. 14:6042–6054. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Mukthavaram R, Ouyang X, Saklecha R, Jiang P, Nomura N, Pingle SC, Guo F, Makale M and Kesari S: Effect of the JAK2/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheres. J Transl Med. 13:2692015. View Article : Google Scholar : PubMed/NCBI | |
|
Fuh B, Sobo M, Cen L, Josiah D, Hutzen B, Cisek K, Bhasin D, Regan N, Lin L, Chan C, et al: LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. Br J Cancer. 100:106–112. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ball S, Li C, Li PK and Lin J: The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells. PLoS One. 6:e188202011. View Article : Google Scholar : PubMed/NCBI | |
|
Sai K, Wang S, Balasubramaniyan V, Conrad C, Lang FF, Aldape K, Szymanski S, Fokt I, Dasgupta A, Madden T, et al: Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway. J Neurooncol. 107:487–501. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Han TJ, Cho BJ, Choi EJ, Kim DH, Song SH, Paek SH and Kim IA: Inhibition of STAT3 enhances the radiosensitizing effect of temozolomide in glioblastoma cells in vitro and in vivo. J Neurooncol. 130:89–98. 2016. View Article : Google Scholar : PubMed/NCBI |
